Covaxin safe for children aged 2-18 years, says Bharat Biotech
Monday, January 30, 2023
  • Circulation
  • Advertise
  • About Us
  • Contact Us
Organiser
  • ‌
  • Bharat
  • World
  • G20
  • Editorial
  • Analysis
  • Opinion
  • Sports
  • More
    • Defence
    • RSS in News
    • Azadi Ka Amrit Mahotsav
    • My States
    • Vocal4Local
    • Business
    • Special Report
    • Culture
    • Sci & Tech
    • Entertainment
    • Education
    • Books
    • Interviews
    • Travel
    • Health
    • Obituary
SUBSCRIBE
No Result
View All Result
  • ‌
  • Bharat
  • World
  • G20
  • Editorial
  • Analysis
  • Opinion
  • Sports
  • More
    • Defence
    • RSS in News
    • Azadi Ka Amrit Mahotsav
    • My States
    • Vocal4Local
    • Business
    • Special Report
    • Culture
    • Sci & Tech
    • Entertainment
    • Education
    • Books
    • Interviews
    • Travel
    • Health
    • Obituary
No Result
View All Result
Organiser
No Result
View All Result
  • Home
  • Bharat
  • World
  • G20
  • Editorial
  • Opinion
  • Analysis
  • Culture
  • Defence
  • RSS in News
  • My States
  • Vocal4Local
  • Subscribe
Home Bharat

Covaxin safe for children aged 2-18 years, says Bharat Biotech

Bharat Biotech has a stockpile of more than 50 million doses of COVAXIN ready to be distributed as required.

WEB DESK by WEB DESK
Jun 17, 2022, 04:33 pm IST
in Bharat
COVAXIN

COVAXIN

Share on FacebookShare on TwitterTelegramEmail

Hyderabad (Telangana): Bharat Biotech International Limited (BBIL) on Thursday announced that Covaxin, its whole-virion inactivated COVID-19 vaccine has proven to be safe, well-tolerated, and highly immunogenic in paediatric subjects in phase II/III study, said a press release.

The study has been accepted and published in Lancet Infectious Diseases, a peer-reviewed high-impact factor journal, added the statement.

Bharat Biotech had conducted phase II/III, open-label, and multicentre studies to evaluate the safety, reactogenicity, and immunogenicity of COVAXIN in healthy children and adolescents in the 2-18 years of age group. The clinical trial conducted in the pediatric population between June 2021 to September 2021 has shown safety, less reactogenic, and robust immunogenicity. The data was submitted to the Central Drugs Standard Control Organisation (CDSCO) in October 2021 and received a nod for emergency use in children aged 6-18years.

Dr. Krishna Ella, Chairman and Managing Director, Bharat Biotech, said, “Safety of the vaccine is critical for children and we are glad to share that COVAXIN has now proven data for safety and immunogenicity in children. We have now achieved our goal of developing a safe and efficacious COVID-19 vaccine for adults and children, for primary immunization and booster doses, and making COVAXIN a universal vaccine. It has proven to be a highly safe vaccine based on data from more than 50 million doses administered to children in India. Vaccines are a great preventive tool; the power of vaccines can only be harnessed if used prophylactically.”

In the study, no serious adverse event was reported. A total of 374 adverse events were reported, and the majority of adverse events were mild in nature and resolved within 1 day. Pain at the injection site was the most commonly reported adverse event.

COVAXIN is formulated uniquely such that the same dosage can be administered to adults and children alike, for primary and booster doses, making it truly a universal vaccine. COVAXIN is a ready-to-use liquid vaccine, stored at 2-8°C, with 12 months shelf life and a multi-dose vial policy.

The whole virion inactivated vaccines have proven to be safe, and tolerable with a safety track record of several decades. Several paediatric vaccines manufactured using this platform technology are utilized in routine immunization for primary immunization and booster doses. Several flu vaccines also utilize this manufacturing platform technology, which is safe and effective for repeated annual immunization doses and boosters.

Bharat Biotech has a stockpile of more than 50 million doses of COVAXIN ready to be distributed as required. Bharat Biotech has established COVAXIN manufacturing to reach an annualised capacity of 1 billion doses by the end of 2021. (ANI)

 

Topics: Bharat BiotechCOVID19IndiaCOVAXIN
ShareTweetSendShareSend
Previous News

China Blocks India’s Move To List Pakistan-Based Abdul Rehman Makki As Global Terrorist

Next News

Jammu And Kashmir: 3 Hizb-ul-Mujahideen terrorists including school teacher Rajni Bala’s murderers neutralized

Related News

Strengthening India’s military prowess to deal with global challenges

Strengthening India’s military prowess to deal with global challenges

Mood of the nationalists ‘upbeat’, Naya Jammu & Kashmir means peaceful Republic Day

Mood of the nationalists ‘upbeat’, Naya Jammu & Kashmir means peaceful Republic Day

Meet the Padma people of the tribal heartland of India

Meet the Padma people of the tribal heartland of India

Indus Waters Treaty: India sends notice to Pakistan on the Treaty, blames it for ‘intransigence’

Indus Waters Treaty: India sends notice to Pakistan on the Treaty, blames it for ‘intransigence’

Washington calls Delhi an ‘important ally’, says it’s monitoring India-China border situation

Washington calls Delhi an ‘important ally’, says it’s monitoring India-China border situation

On Republic Day, Bharat Biotech launches first India-made nasal Covid Vaccine

On Republic Day, Bharat Biotech launches first India-made nasal Covid Vaccine

Comments

The comments posted here/below/in the given space are not on behalf of Organiser. The person posting the comment will be in sole ownership of its responsibility. According to the central government's IT rules, obscene or offensive statement made against a person, religion, community or nation is a punishable offense, and legal action would be taken against people who indulge in such activities.

Latest News

Ram Mandir: Nepal dispatches two Shaligram rocks to Ayodhya for Bhagwan Sri Ram, Maa Janaki idols – Key details

Ram Mandir: Nepal dispatches two Shaligram rocks to Ayodhya for Bhagwan Sri Ram, Maa Janaki idols – Key details

Tripura Assembly Polls 2023: CM Manik Saha files nomination for State polls; Assam CM and Manipur CM accompanied him

Tripura Assembly Polls 2023: CM Manik Saha files nomination for State polls; Assam CM and Manipur CM accompanied him

Ramcharitmanas Row: FIR against OBC Mahasabha members and Swami Prasad Maurya for burning copies of Ramcharitmanas

Ramcharitmanas Row: FIR against OBC Mahasabha members and Swami Prasad Maurya for burning copies of Ramcharitmanas

BBC and its impudence-Here are details

BBC and its impudence-Here are details

Chinese government’s Propaganda Department monitors content on China Portrayed to the World

Chinese government’s Propaganda Department monitors content on China Portrayed to the World

BBC is a serial offender; its hate for India is widely known

BBC is a serial offender; its hate for India is widely known

Tamil Nadu: ‘I razed century-old temple – a Saraswati temple, a Lakshmi temple & a Parvati temple,’ says DMK MP TR Baalu

Tamil Nadu: ‘I razed century-old temple – a Saraswati temple, a Lakshmi temple & a Parvati temple,’ says DMK MP TR Baalu

Adani Group answers all 88 questions raised by Hindenburg Research; including age of its auditors

Adani Group answers all 88 questions raised by Hindenburg Research; including age of its auditors

BBC Documentary: A deep conspiracy against India

BBC Documentary: A deep conspiracy against India

Blustering BBC’s Bluff

Blustering BBC’s Bluff

  • Privacy
  • Terms
  • Cookie Policy
  • Refund and Cancellation
  • Delivery and Shipping

© Bharat Prakashan (Delhi) Limited.
Tech-enabled by Ananthapuri Technologies

No Result
View All Result
  • Home
  • Bharat
  • World
  • Editorial
  • Analysis
  • Opinion
  • Defence
  • Culture
  • Sports
  • Business
  • RSS in News
  • My States
  • Vocal4Local
  • Special Report
  • Sci & Tech
  • Entertainment
  • Education
  • Books
  • Interviews
  • Travel
  • Health
  • Obituary
  • Subscribe
  • Advertise
  • Circulation
  • About Us
  • Contact Us
  • Privacy Policy
  • Cookie Policy
  • Terms of Use
  • Refund and Cancellation

© Bharat Prakashan (Delhi) Limited.
Tech-enabled by Ananthapuri Technologies